Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $147.01. The company's market cap stands at 186.21B, with a P/E ratio of 22.13 and a dividend yield of 2.1%.
On 2026-03-03, Gilead Sciences(GILD) stock traded between a low of $147.01 and a high of $147.01. Shares are currently priced at $147.01, which is 0.0% above the low and 0.0% below the high.
The Gilead Sciences(GILD)'s current trading volume is 1.78K, compared to an average daily volume of 7.23M.
In the last year, Gilead Sciences(GILD) shares hit a 52-week high of $157.29 and a 52-week low of $93.37.
In the last year, Gilead Sciences(GILD) shares hit a 52-week high of $157.29 and a 52-week low of $93.37.
GILD News
Advertisement What Gilead Sciences stock is offering investors right now Gilead Sciences (GILD) is back on investors’ radar as its shares trade around $148.95...
Analyst Michael Yee of UBS maintained a Buy rating on Gilead Sciences, retaining the price target of $175.00. Michael Yee has given his Buy rating due to a com...
Gilead Sciences (NasdaqGS:GILD) has agreed to acquire Arcellx in a $7.8b deal, expanding its presence in cell therapies for blood cancers. The acquisition adds...
Analyst ratings
72%
of 32 ratingsMore GILD News
Gilead (GILD) Sciences announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigatio...
Arcellx Inc. (NASDAQ:ACLX) shares rose on Wednesday after Gilead Sciences Inc. (NASDAQ:GILD) agreed to acquire the company for $7.8 billion, or $115 per share i...
Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Gilead Sciences and keeping the price target at $162.00. Tazeen Ahmad has given...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.